A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma

Inclusion Criteria: * Patients with metastatic pancreatic cancer. * Must have adenocarcinoma component (presence of combined histology is acceptable, as long as adenocarcinoma is present). * Weight loss from baseline of at least 5% (Baseline weight can be anytime from diagnosis onward). * Must have a tissue-based confirmation of diagnosis available. Tissue does not need to be a metastasis; primary tumor or prior surgery are acceptable sources. * Must have had progression of disease after one prior line of therapy in the metastatic setting. * Must be receiving or plan to receive another line of therapy in the metastatic setting. o If therapy is being administered outside MD Anderson, the patient is still eligible for this trial. o Enrollment onto a therapeutic clinical trial as this second line therapy is not explicitly excluded. * Must have triple ECG results available. Patients will be ineligible if they present: o Second- or third-degree block. * Prolonged QT wave. * Atrial fibrillation or flutter. * Uncontrolled ventricular fibrillation or flutter. * Premature ventricular contractions (PVC). Exclusion Criteria: Exclusion Criteria * History of cervical vagotomy on the right side of neck. * Known structural abnormalities on the right side of neck, including but not limited to situs inversus, bulky R-neck lymphadenopathy, etc., that in the investigators' opinion would lead to inability to correctly place the device onto the vagus nerve. * Implanted electrical device that passes through the neck (e.g.: cranial implant with battery pack in chest, and wires running through the neck). * Metal implants in the neck, including the cervical spine. * Recent (6 months or less) nerve block or botox injections to the head or neck. * Pain specifically localized to the treatment area, the right side of the neck. * Prior severe cerebrovascular disease (e.g., intracranial aneurysm, intracranial hemorrhage, stroke). * Prior severe cardiac disease, including but not limited to coronary artery disease (CAD), prior myocardial infarction (MI), uncontrolled congestive heart failure (CHF).